Hyperparathyroidism, Primary
Conditions
Keywords
Hyperparathyroidism, Primary, cinacalcet
Brief summary
This multicenter, open-label, single-arm, extension study was designed to evaluate long-term tolerability, safety, and efficacy of cinacalcet. Subjects were enrolled immediately after they completed the parent study, 990120. All subjects began treatment with 30 mg cinacalcet twice daily (BID), with dose adjustments made per protocol-specified guidelines. The study consisted of 2 consecutive phases that occurred in the following order: a dose-titration phase lasting 12 weeks and a maintenance phase lasting approximately 4½ years.
Interventions
DRUGcinacalcet
Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
Sponsors
Amgen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Successfully completed the parent study 990120 * Agreed to use highly effective (in the opinion of the principal investigator) contraceptive measures throughout the study * Were able to comprehend and were willing to give written informed consent for participation in the study
Exclusion criteria
* Pregnant or breast-feeding * Had a psychiatric disorder that interfered with the understanding and giving of informed consent or compliance with protocol requirements * Had any other condition that reduced the chance of obtaining data (eg, known poor compliance) * Participating in another investigational study at the time of study entry * Had any unstable medical condition, defined as having been hospitalized within 28 days before day 1, or otherwise unstable in the judgment of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nature, frequency, severity, and relationship to treatment of adverse events | 234 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Calcium levels and plasma iPTH during the maintenance phase | 234 weeks |
| Percentage changes in BMD from baseline of the parent study to each measurement time point and absolute BMD values, as assessed by DXA scans of proximal femur, lumbar spine (L1-L4), forearm, and total body scans | 234 weeks |
Outcome results
None listed